AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16343498 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin infusion 20 units
Number of subjects: 100
Study 14759306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (NNS)
Number of subjects: 38
Study 11061198 — intervention group
Group type: COMPARATOR
Intervention: Active trans-femoral and trans-tibial amputees
Number of subjects: 18
Study 11061198 — intervention group
Group type: COMPARATOR
Intervention: Intact limb ankle
Number of subjects: 18
Study 11061198 — intervention group
Group type: COMPARATOR
Intervention: Intact limb knee
Number of subjects: 18
Study 11061198 — intervention group
Group type: COMPARATOR
Intervention: Intact limb hip
Number of subjects: 18
Study 8621132 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg/d for 6 weeks)
Number of subjects: 20
Study 8621132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10147050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-saving and cost-containment measures
Number of subjects: 0
Study 10147050 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods
Number of subjects: 0
Study 10147050 — intervention group
Group type: EXPERIMENTAL
Intervention: Large scale trials
Number of subjects: 0
Study 3977064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg orally
Number of subjects: 40
Study 3977064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg intravenously
Number of subjects: 40
Study 3977064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate 30 ml orally
Number of subjects: 40
Study 3977064 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 40
Study 29961998 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 1545
Study 29961998 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 1 to 4 mg
Number of subjects: 1545
Study 26022721 — intervention group
Group type: EXPERIMENTAL
Intervention: on line high efficiency hemodiafiltration (HDF)
Number of subjects: 20
Study 26022721 — intervention group
Group type: COMPARATOR
Intervention: high-flux hemodialysis (HD)
Number of subjects: 20
Study 26022721 — intervention group
Group type: EXPERIMENTAL
Intervention: both HD and HDF
Number of subjects: 20
Study 25675992 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.3 mg/24 h rivastigmine patch
Number of subjects: 0
Study 25675992 — intervention group
Group type: COMPARATOR
Intervention: 4.6 mg/24 h rivastigmine patch
Number of subjects: 0
Study 24257390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 25
Study 24257390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium + Albuterol
Number of subjects: 25
Study 24257390 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 25
Study 24257390 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium + Albuterol
Number of subjects: 25
Study 20554769 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermostatic mixing valves (TMVs) fitted by a qualified plumber and educational leaflets
Number of subjects: 124
Study 20554769 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermostatic mixing valves (TMVs)
Number of subjects: 124
Study 19025232 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Modification Program (AMP)
Number of subjects: 0
Study 19025232 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Condition (ACC)
Number of subjects: 0
Study 16511727 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 16511727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15610805 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxytetracycline plus topical placebo
Number of subjects: 649
Study 15610805 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral minocycline plus topical placebo
Number of subjects: 649
Study 15610805 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide plus oral placebo
Number of subjects: 649
Study 15610805 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical erythromycin and benzoyl peroxide in a combined formulation plus oral placebo
Number of subjects: 649
Study 15610805 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical erythromycin and benzoyl peroxide separately plus oral placebo
Number of subjects: 649
Study 15610805 — intervention group
Group type: COMPARATOR
Intervention: Minocycline versus oxytetracycline
Number of subjects: 649
Study 15610805 — intervention group
Group type: COMPARATOR
Intervention: Combined erythromycin and benzoyl peroxide versus oxytetracycline
Number of subjects: 649
Study 15610805 — intervention group
Group type: COMPARATOR
Intervention: Combined erythromycin and benzoyl peroxide versus minocycline
Number of subjects: 649
Study 15610805 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin and benzoyl peroxide separately versus combined formulation
Number of subjects: 649
Study 15610805 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide versus oxytetracycline
Number of subjects: 649
Study 15610805 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide versus minocycline
Number of subjects: 649
Study 15610805 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide versus combined formulation
Number of subjects: 649
Study 11825333 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day
Number of subjects: 0
Study 11825333 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 0
Study 11825333 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (both dosages)
Number of subjects: 0
Study 11825333 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0
Study 9205760 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine (150, 300, 400, 500, 600, 800 mg)
Number of subjects: 0
Study 8182977 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient preoperative evaluation
Number of subjects: 355
Study 8182977 — intervention group
Group type: COMPARATOR
Intervention: Inpatient preoperative evaluation
Number of subjects: 355
Study 3062906 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (20 micrograms PGE 1)
Number of subjects: 50
Study 3062906 — intervention group
Group type: COMPARATOR
Intervention: Placebo (646.7 micrograms alpha‐cyclodextrin)
Number of subjects: 50
Study 31917765 — intervention group
Group type: EXPERIMENTAL
Intervention: Double low-dose group (n = 35)
Number of subjects: 67
Study 31917765 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose group (n = 32)
Number of subjects: 67
Study 28787186 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 400 mg
Number of subjects: 0
Study 28787186 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 800 mg
Number of subjects: 0
Study 28787186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27391985 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient general psychiatric treatment
Number of subjects: 110
Study 25590930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 30)
Number of subjects: 61
Study 25590930 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 31)
Number of subjects: 61
Study 25590930 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study 22459275 — intervention group
Group type: EXPERIMENTAL
Intervention: FKBP5 rs9296158
Number of subjects: 130
Study 22459275 — intervention group
Group type: EXPERIMENTAL
Intervention: FKBP5 rs9470080
Number of subjects: 130
Study 22459275 — intervention group
Group type: EXPERIMENTAL
Intervention: FKBP5 rs1360780
Number of subjects: 130
Study 20459655 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR Educational Program (blended learning intervention)
Number of subjects: 244
Study 18931495 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosion only (EO) - cola drink 3 times/day
Number of subjects: 11
Study 18931495 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosion + plaque (EP) - cola drink 3 times/day with plaque
Number of subjects: 11
Study 18931495 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosion + caries (EC) - cola drink 3 times/day + sucrose solution 8 times/day with plaque
Number of subjects: 11
Study 18931495 — intervention group
Group type: COMPARATOR
Intervention: Caries only (CO) - sucrose solution 8 times/day with plaque
Number of subjects: 11
Study 15847192 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (20 microg over 6 hours for 5 consecutive days)
Number of subjects: 36
Study 15847192 — intervention group
Group type: COMPARATOR
Intervention: Core decompression
Number of subjects: 36
Study 14744417 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly prepared patches
Number of subjects: 71
Study 14744417 — intervention group
Group type: COMPARATOR
Intervention: Previously prepared and stored patches
Number of subjects: 71
Study 10977380 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Circle (HC) sessions
Number of subjects: 17
Study 10977380 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 17
Study 8677869 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance cardiography
Number of subjects: 25
Study 8677869 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution
Number of subjects: 25
Study 8677869 — intervention group
Group type: COMPARATOR
Intervention: Direct Fick
Number of subjects: 25
Study 1804595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus amikacin
Number of subjects: 100
Study 1804595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus amikacin
Number of subjects: 100
Study 1804595 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 100
Study 6403546 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent oral poliomyelitis vaccine prepared from monkey kidney cells
Number of subjects: 50
Study 6403546 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent oral poliomyelitis vaccine prepared from human diploid cells (MRC5)
Number of subjects: 50
Study 6403546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31576697 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus durvalumab and tremelimumab
Number of subjects: 24
Study 31576697 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy plus durvalumab
Number of subjects: 24
Study 30032978 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine-based screening with Alere Determine TB-LAM Ag and Xpert assays
Number of subjects: 2574
Study 30032978 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (no urine testing for tuberculosis)
Number of subjects: 2574
Study 30032978 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for CD4 counts less than 100 cells per μL
Number of subjects: 2574
Study 30032978 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for severe anaemia
Number of subjects: 2574
Study 30032978 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for clinically suspected tuberculosis
Number of subjects: 2574
Study 26341916 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube feeding
Number of subjects: 35
Study 26341916 — intervention group
Group type: COMPARATOR
Intervention: Nil per os
Number of subjects: 35
Study 1442907 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized cold therapy to the cesarean section incision
Number of subjects: 62
Study 1442907 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative care
Number of subjects: 62
Study 22729756 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic therapy (KT) using oscillating beds (TryaDyne Proventa, KCI)
Number of subjects: 89
Study 22729756 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 89
Study 19483641 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation to the dorsolateral prefrontal cortex
Number of subjects: 1
Study 19483641 — intervention group
Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation to the dorsolateral prefrontal cortex
Number of subjects: 1
Study 18369092 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Fructose (0.3 g/min)
Number of subjects: 10
Study 18369092 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-Fructose (0.5 g/min)
Number of subjects: 10
Study 18369092 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fructose (0.7 g/min)
Number of subjects: 10
Study 18369092 — intervention group
Group type: COMPARATOR
Intervention: No-Fructose (0.0 g/min)
Number of subjects: 10
Study 15787663 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone up to 45 mg once daily
Number of subjects: 1270
Study 15787663 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide up to 160 mg two times daily
Number of subjects: 1270
Study 15787663 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 1270
Study 15787663 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 1270
Study 12095805 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrimethamine and azithromycin
Number of subjects: 46
Study 12095805 — intervention group
Group type: COMPARATOR
Intervention: pyrimethamine and sulfadiazine
Number of subjects: 46
Study 10844383 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional AV fistula (group 1)
Number of subjects: 61
Study 10844383 — intervention group
Group type: COMPARATOR
Intervention: Closed AV fistula (group 2)
Number of subjects: 61
Study 8960854 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 36
Study 8960854 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide treatment
Number of subjects: 36
Study 2013140 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hospital discharge on day 4 after aggressive interventional therapy
Number of subjects: 580
Study 2013140 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model for predicting absence of late major complications
Number of subjects: 580
Study 6233635 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 39
Study 6233635 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 39
Study 31241756 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltreatment exposure (MACE score of 1 or higher)
Number of subjects: 202
Study 31241756 — intervention group
Group type: COMPARATOR
Intervention: No maltreatment exposure (MACE score of 0)
Number of subjects: 202
Study 31241756 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective self-report of physical maltreatment between ages 3-6
Number of subjects: 202
Study 31241756 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective self-report of peer emotional abuse at ages 13-15
Number of subjects: 202
Study 31241756 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical maltreatment at age 4
Number of subjects: 202
Study 31241756 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal emotional abuse at age 13
Number of subjects: 202
Study 31241756 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer emotional abuse at age 6
Number of subjects: 202
Study 31241756 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer emotional abuse at age 13
Number of subjects: 202
Study 30151823 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg methylprednisolone
Number of subjects: 117
Study 30151823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 26950475 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone (NETA)
Number of subjects: 84
Study 26950475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 84
Study 26950475 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-Releasing Intrauterine System (LNG-IUS)
Number of subjects: 84
Study 26950475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid and Levonorgestrel-Releasing Intrauterine System (LNG-IUS)
Number of subjects: 84
Study 25311285 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET), 50-minute session
Number of subjects: 174
Study 25311285 — intervention group
Group type: COMPARATOR
Intervention: Education-only intervention, 15-minute session
Number of subjects: 174
Study 22882198 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic wound infiltration plus patient-controlled opiate analgesia (WI group)
Number of subjects: 65
Study 22882198 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (EP group)
Number of subjects: 65
Study 18793813 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS with predilation (n=100)
Number of subjects: 205
Study 18793813 — intervention group
Group type: COMPARATOR
Intervention: Direct stenting (DS, n=105)
Number of subjects: 205
Study 18793813 — intervention group
Group type: COMPARATOR
Intervention: Direct stenting (DS)
Number of subjects: 205
Study 18793813 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS with predilation
Number of subjects: 205
Study 18793813 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 205
Study 21605403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention programme to improve adherence to recommendations to reduce the use of urethral catheters
Number of subjects: 2943
Study 15735106 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplement
Number of subjects: 0
Study 15735106 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multiple micronutrient supplement
Number of subjects: 0
Study 15735106 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly multiple micronutrient supplement with daily placebo
Number of subjects: 0
Study 15735106 — intervention group
Group type: COMPARATOR
Intervention: Daily placebo supplement
Number of subjects: 0
Study 12898888 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic dental care interventions focusing on prophylactics, education, and treatment
Number of subjects: 0
Study 9850354 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) parameters (BUA, SOS, Stiffness)
Number of subjects: 24
Study 9850354 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) measured by DXA (hip, lumbar spine, whole body)
Number of subjects: 24
Study 9850354 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition (lean tissue and fat mass)
Number of subjects: 24
Study 7976149 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.5 microgram kg‐1 min‐1)
Number of subjects: 40
Study 7976149 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (0.5 or 2.5 micrograms kg‐1 min‐1)
Number of subjects: 40
Study 7976149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2728925 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride and calcitriol
Number of subjects: 78
Study 2728925 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride and calcium
Number of subjects: 78
Study 2728925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 2728925 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol alone
Number of subjects: 78
Study 29684999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano copper (100 mg/kg/day)
Number of subjects: 28
Study 29684999 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper sulfate (CuSO4) (50, 100, and 200 mg/kg/day)
Number of subjects: 28
Study 29684999 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal standard diet)
Number of subjects: 28
Study 27573786 — intervention group
Group type: EXPERIMENTAL
Intervention: da Vinci Surgical Skills Simulator (dVSSS)
Number of subjects: 26
Study 27573786 — intervention group
Group type: COMPARATOR
Intervention: Standard da Vinci (SdV)
Number of subjects: 26
Study 26111528 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and child health (MCH) nurse-designed model for DV screening and care
Number of subjects: 10271
Study 26111528 — intervention group
Group type: EXPERIMENTAL
Intervention: MCH nurse-designed model for DV screening and care
Number of subjects: 10271
Study 26111528 — intervention group
Group type: COMPARATOR
Intervention: Usual care (government mandated face-to-face DV screening)
Number of subjects: 10271
Study 23253122 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 238
Study 23253122 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 238
Study 23253122 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 238
Study 20681336 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Self‐focus Meditation (weekly 1‐hr. training sessions for 5 weeks)
Number of subjects: 42
Study 20681336 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list Control group
Number of subjects: 42
Study 19026808 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol as first-line antihypertensive medication in the operating room
Number of subjects: 118
Study 19026808 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of esmolol and sodium nitroprusside (Nipride)
Number of subjects: 118
Study 19026808 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medications at discharge
Number of subjects: 118
Study 17217606 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mammography screening
Number of subjects: 6000
Study 17217606 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of disease stage in the cohort offered screening
Number of subjects: 6000
Study 12813334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative management (NOM)
Number of subjects: 12
Study 11061200 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-anchored prostheses
Number of subjects: 32
Study 11061200 — intervention group
Group type: EXPERIMENTAL
Intervention: Socket prostheses
Number of subjects: 32
Study 11061200 — intervention group
Group type: COMPARATOR
Intervention: Control limbs (contralateral side)
Number of subjects: 32
Study 8856516 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-based intervention (told not to play with guns)
Number of subjects: 48
Study 8856516 — intervention group
Group type: COMPARATOR
Intervention: Access to a parent's firearm
Number of subjects: 48
Study 8856516 — intervention group
Group type: COMPARATOR
Intervention: Gun play and handling of firearms in the home
Number of subjects: 48